The current treatment for wet age-related macular degeneration (AMD) includes monthly intravitreal injections of antibody therapeutics targeting the vascular endothelial growth factor (VEGF) such as ranibizumab, aflibercept, and brolucizumab [2]. Here, VEGFA is linked to wet macular degeneration.